New prospective on adjuvant treatment for gastrointestinal stromal tumors.
- Author:
Zhi-zhong PAN
1
;
Xiao-jun WU
Author Information
1. Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Guangdong 510060, China. panzz@sysucc.org.cn
- Publication Type:Journal Article
- MeSH:
Benzamides;
therapeutic use;
Chemotherapy, Adjuvant;
Gastrointestinal Neoplasms;
drug therapy;
surgery;
Gastrointestinal Stromal Tumors;
drug therapy;
surgery;
Humans;
Imatinib Mesylate;
Piperazines;
therapeutic use;
Pyrimidines;
therapeutic use
- From:
Chinese Journal of Gastrointestinal Surgery
2013;16(3):212-215
- CountryChina
- Language:Chinese
-
Abstract:
Gastrointestinal stromal tumor (GIST) represents the most common mesenchymal tumor of the gastrointestinal tract. With decades of development, surgical excision combined with molecular targeted agents is becoming the mode for the GIST treatment. Imatinib mesylate (IM) is the first-line therapy medicine for GIST adjuvant treatment, and it significantly reduces recurrence or metastasis and increases survival. According to the recently results of SSGXVIII/AIO study, imatinib adjuvant therapy should be administered for at least 3 years for the GIST patients with a high estimated risk of recurrence and metastasis after surgery. Nevertheless, the optimal duration of the adjuvant therapy or the follow-up policy remains unclear, and we look forward to standard assessment criteria for individualized treatment.
